Invezz

Azenta (AZTA)

Nasdaq Market Open

Azenta, Inc. is a life sciences technology company that provides sample management, automated storage and genomic services to pharmaceutical, biotechnology, academic and healthcare research customers. The company supports the handling of biological and chemical materials across the research and development cycle, from early discovery work through later-stage commercial and clinical applications.

Azenta’s core expertise is in preserving, organising and analysing high-value samples. Its Sample Management Solutions business supplies automated storage systems, cryogenic and ultra-cold storage technologies, sample tubes, consumables, instruments, thawing devices and related products. These systems help laboratories and research organisations protect the integrity of samples while improving retrieval, tracking and workflow efficiency. This segment represents the company’s largest source of revenue and reflects Azenta’s background in precision automation and cold-chain technologies.

The company also operates a Multiomics business, which provides genomic analysis and related services. These offerings are used by customers seeking insights from DNA, RNA and other biological data, supporting applications such as drug discovery, translational research and broader life sciences development. Azenta’s informatics and repository services complement these capabilities by helping customers store, track and manage complex sample and data collections.

Azenta serves an international customer base, with operations and revenue exposure across the United States, China, the United Kingdom, Europe and other regions. The United States is its largest market. What distinguishes Azenta is its combination of physical sample infrastructure, laboratory automation, consumables and analytical services, positioning the company as an enabling partner for organisations that depend on reliable biological sample preservation and data generation.

22.99 USD
−0.89 (-3.73%)

Last updated

Market Cap
1.1B
P/E
P/FCF
36.65
P/S
1.85
Enterprise Value
867.12M
Sector
Industrials
Industry
Special Industry Machinery, Not Elsewhere Classified
Address
200 SUMMIT DRIVE, BURLINGTON, MA, 01803
GlobeNewswire Inc.

Levi & Korsinsky Announces Investigation of Securities Claims Against Azenta, Inc. (AZTA)

May 21, 2026, 09:00 AM
GlobeNewswire Inc.

Bragar Eagel & Squire, P.C. is Investigating Azenta, Inc. (NASDAQ:AZTA) on Behalf of Azenta Stockholders and Encourages Investors to Contact the Firm

May 19, 2026, 18:23 PM
GlobeNewswire Inc.

AZTA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 18, 2026, 19:00 PM
GlobeNewswire Inc.

AZTA Investors Have Opportunity to Join Azenta, Inc. Fraud Investigation with the Schall Law Firm

May 18, 2026, 14:43 PM
GlobeNewswire Inc.

AZTA SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Azenta, Inc. for Possible Securities Law Violations

May 14, 2026, 09:00 AM
GlobeNewswire Inc.

AZTA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 13, 2026, 19:00 PM
GlobeNewswire Inc.

AZENTA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Azenta, Inc. on Behalf of Azenta Stockholders and Encourages Investors to Contact the Firm

May 12, 2026, 17:53 PM
GlobeNewswire Inc.

Bio-Preservation Market to Reach US$ 44.45 Billion by 2035 | Cold Chain Expansion and Cell & Gene Therapy Commercialization Drive Growth Says Astute Analytica

Feb 11, 2026, 13:40 PM
GlobeNewswire Inc.

Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™

Oct 08, 2025, 11:00 AM
GlobeNewswire Inc.

Biobanking Market to Reach Market Valuation of USD 95.5 Billion by 2031 | SkyQuest Technology

Nov 13, 2024, 19:40 PM
GlobeNewswire Inc.

Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider

Aug 07, 2024, 09:01 AM
Zacks Investment Research

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop - Zacks Investment Research

Jul 16, 2024, 10:00 AM
Zacks Investment Research

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates

May 03, 2024, 08:15 AM
Zacks Investment Research

Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates

Feb 06, 2024, 17:35 PM
Zacks Investment Research

Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?

Feb 05, 2024, 10:00 AM
Zacks Investment Research

Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?

Jan 03, 2024, 07:23 AM
Zacks Investment Research

3 Stocks to Watch After Impressive Earnings Beats

Nov 14, 2023, 21:47 PM
MarketWatch

S&P 500, Nasdaq post best day since April as subdued inflation reading sparks buying frenzy

Nov 14, 2023, 16:28 PM
Zacks Investment Research

Azenta (AZTA) Beats Q3 Earnings and Revenue Estimates

Aug 08, 2023, 18:40 PM
Zacks Investment Research

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

Aug 01, 2023, 17:25 PM
Market Cap
1.1B
Enterprise Value
867.12M
P/E
P/B
0.71
P/S
1.85
EV / EBITDA
23.54
EV / Sales
1.45
EPS
-3.87
Dividend Yield
0%
P/FCF
36.65
P/CF
17.66
Free Cash Flow
30.05M
ROE
-11.46%
ROA
-9.36%
Debt / Equity
0
Current Ratio
3.08
Quick Ratio
2.74
Cash
0.99
Avg Volume
1.4M
Fundamentals Snapshot Price
23.89

Income Statement

Line Item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Revenue 144.8M 148.64M 158.95M 143.94M 143.34M
Gross profit 62.04M 63.71M 67.96M 67.76M 62.78M
Operating income -165.79M -7.24M 1.37M -714K -18.19M
EBITDA -1.28M 7.55M 15.81M 14.76M -661K
Net income -160.8M -15.43M 50.84M -52.81M -47.66M
Basic EPS -3.49 -0.34 1.11 -1.15 -1.04
Diluted EPS -3.49 -0.34 1.11 -1.15 -1.04

Balance Sheet

Line Item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Total assets 1.9B 2.07B 2.06B 2.02B 2.04B
Total liabilities 349.21M 359.6M 332.6M 345.5M 340.43M
Total equity 1.55B 1.71B 1.73B 1.67B 1.7B
Cash & equivalents 234.03M 336.63M 279.78M 270.04M 253.64M
Current assets 724.58M 777.51M 705.98M 676.17M 708.49M
Current liabilities 235.45M 243.65M 223.7M 230.81M 224.87M

Cash Flow

Line Item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Operating cash flow 13.51M 20.85M 2.17M 25.81M 14.4M
Investing cash flow -114.75M 36.77M 826K -29.7M -138.67M
Financing cash flow 980K -2.63M 817K -128K -5.15M
Change in cash -102.7M 55.3M 2.87M 4.95M -125.57M
Kind Filing Date Link
edgar index SD — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
form 4 Form 4 — Cornog William L View Filing
form 4 Form 4 — Starr Ephraim View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index S-8 — Azenta, Inc. View Filing
edgar index 10-Q — Azenta, Inc. View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G — Azenta, Inc. View Filing
edgar index 3 — Azenta, Inc. View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — Azenta, Inc. View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4/A — Azenta, Inc. View Filing
form 4 Form 4 — Nova Tina Susan View Filing
edgar index 10-Q — Azenta, Inc. View Filing
form 4 Form 4 — Koffey Quentin View Filing
form 4 Form 4 — Koffey Quentin View Filing
form 4 Form 4 — Davis Robyn C View Filing
form 4 Form 4 — McLaughlin Erica View Filing
form 4 Form 4 — Casal Frank View Filing
form 4 Form 4 — Doshi Dipal View Filing
form 4 Form 4 — Madaus Martin D View Filing
form 4 Form 4 — Cornog William L View Filing
form 4 Form 4 — Cornog William L View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — Azenta, Inc. View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index ARS — Azenta, Inc. View Filing
edgar index DEFR14A — Azenta, Inc. View Filing
edgar index DEF 14A — Azenta, Inc. View Filing
edgar index DEFA14A — Azenta, Inc. View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 10-K — Azenta, Inc. View Filing
ten k section 10-K — business View Filing
ten k section 10-K — risk_factors View Filing
edgar index 4/A — Azenta, Inc. View Filing
edgar index NT 10-K — Azenta, Inc. View Filing
edgar index 4/A — Azenta, Inc. View Filing
edgar index 4/A — Azenta, Inc. View Filing
edgar index 4/A — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
edgar index 4 — Azenta, Inc. View Filing
form 4 Form 4 — Starr Ephraim View Filing
form 4 Form 4 — Zhou Ginger View Filing
form 4 Form 4 — Pirogova Olga View Filing
form 4 Form 4 — Lin Lawrence Y. View Filing
form 4 Form 4 — Marotta John View Filing
form 4 Form 4 — Marotta John View Filing
edgar index 8-K — Azenta, Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Azenta, Inc. View Filing